Skip to Main Content

Paper Details

"Game Changer": Health Professionals' Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management.
Oncologist
3
2022
Circulating Tumor DNA, HCS, Hereditary Cancer Syndrome, cancer, circulating, circulating tumor DNA, ctDNA, hereditary cancer syndrome, nurse, participants, patients
Author NameAffiliation
William D FoulkesMcGill University
William D FoulkesJewish General Hospital
William D FoulkesMcGill University
William D FoulkesJewish General Hospital
Kasmintan A Schrader
Kasmintan A SchraderUniversity of British Columbia
Kasmintan A Schrader
Kasmintan A SchraderUniversity of British Columbia
Aaron PollettMount Sinai Hospital
Trevor J PughPrincess Margaret Cancer Centre, University Health Network
Trevor J PughOntario Institute for Cancer Research
Trevor J PughPrincess Margaret Cancer Centre, University Health Network
Trevor J PughOntario Institute for Cancer Research
Raymond H KimUniversity of Toronto
Raymond H KimPrincess Margaret Cancer Centre, University Health Network
Raymond H KimMount Sinai Hospital
Raymond H KimThe Hospital for Sick Children
  • 1 - 17

Datasets

Release 1.2